William H. Frishman mainly focuses on Internal medicine, Pharmacology, Cardiology, Endocrinology and Anesthesia. His research related to Disease, Angina, Heart failure, Incidence and Beta-adrenergic blocking agent might be considered part of Internal medicine. His studies in Angina integrate themes in fields like Placebo, Clinical trial, Ventricular Tachyarrhythmias and Heart rate.
In general Pharmacology, his work in Clinical pharmacology is often linked to Blocking linking many areas of study. His study brings together the fields of Fibrinogen and Cardiology. His Anesthesia research includes themes of Artery and Coronary artery bypass surgery.
William H. Frishman focuses on Internal medicine, Cardiology, Anesthesia, Pharmacology and Blood pressure. Disease is closely connected to Endocrinology in his research, which is encompassed under the umbrella topic of Internal medicine. As a part of the same scientific study, he usually deals with the Cardiology, concentrating on Verapamil and frequently concerns with Calcium channel.
His study looks at the intersection of Anesthesia and topics like Placebo with Adverse effect, Combination therapy and Essential hypertension. His Drug, Pharmacokinetics and Side effect study in the realm of Pharmacology connects with subjects such as Blocking. The concepts of his Blood pressure study are interwoven with issues in Supine position, Urology and Diuretic.
William H. Frishman mostly deals with Internal medicine, Pharmacology, Cardiology, Endocrinology and Disease. William H. Frishman has researched Pharmacology in several fields, including Chelation therapy, Chemotherapy and Blood pressure. The study of Cardiology is intertwined with the study of Left ventricular hypertrophy in a number of ways.
His Endocrinology research is multidisciplinary, incorporating elements of Agonist and Receptor. His research in Disease focuses on subjects like Intensive care medicine, which are connected to Smoking status and Complication. His studies deal with areas such as Isradipine, Clinical trial, Nifedipine, Placebo and Heart rate as well as Angina.
William H. Frishman mainly investigates Internal medicine, Pharmacology, Endocrinology, Blood pressure and Anesthesia. His Internal medicine study incorporates themes from Oncology and Cardiology. His Cardiology research includes elements of Platelet and Aspirin.
William H. Frishman interconnects Cardioprotective Agent, Heart failure and Clinical pharmacology in the investigation of issues within Endocrinology. His study in Blood pressure is interdisciplinary in nature, drawing from both Diuretic and Urology. His Anesthesia research is multidisciplinary, incorporating perspectives in Diuresis, Discontinuation, Nifedipine and Agonist, Fenoldopam.
ACCF/AHA 2011 expert consensus document on hypertension in the elderly: A report of the american college of cardiology foundation task force on clinical expert consensus documents
Wilbert S Aronow;Jerome J Fleg;Carl J Pepine;Nancy Trygar Artinian.
Development of dementing illnesses in an 80-year-old volunteer cohort.
R. Katzman;M. Aronson;P. Fuld;C. Kawas.
Annals of Neurology (1989)
ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension
Wilbert S. Aronow;Jerome L. Fleg;Carl J. Pepine;Nancy T. Artinian.
Journal of the American College of Cardiology (2011)
Trends in Incidence, Management, and Outcomes of Cardiogenic Shock Complicating ST-Elevation Myocardial Infarction in the United States
Dhaval Kolte;Sahil Khera;Wilbert S. Aronow;Marjan Mujib.
Journal of the American Heart Association (2014)
Dobutamine: a new synthetic cardioactive sympathetic amine.
Edmund H. Sonnenblick;William H. Frishman;Thierry H. LeJemtel.
The New England Journal of Medicine (1979)
Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy.
Joshua Hartman;William H. Frishman.
Cardiology in Review (2014)
Comparison of Self-Report, Hospital Discharge Codes, and Adjudication of Cardiovascular Events in the Women’s Health Initiative
Susan R. Heckbert;Charles Kooperberg;Monika M. Safford;Bruce M. Psaty.
American Journal of Epidemiology (2004)
Women, myocardial infarction, and dementia in the very old.
M. K. Aronson;W. L. Ooi;H. Morgenstern;A. Hafner.
Co-Enzyme Q10: A New Drug for Cardiovascular Disease
Steven Greenberg;William H. Frishman.
The Journal of Clinical Pharmacology (1990)
Herbal Medicine for the Treatment of Cardiovascular Disease: Clinical Considerations
Nick H. Mashour;George I. Lin;William H. Frishman.
JAMA Internal Medicine (1998)
If you think any of the details on this page are incorrect, let us know.